Abstract
Thrombin a key modulator of the complex process involved in coronary obstruction during acute ST-segment elevation myocardial is infarction. A correct and complete thrombin inhibition has to be achieved early in this setting and is complementary with fast and potent antiplatelet treatment. Bivalirudin, a direct thrombin inhibitor, has clearly shown to be an effective tool for acute coronary syndromes managed invasively, contemporarily causing fewer hemorragies. However, its efficacy has been questioned, mostly in cases of inadequate platelet inhibition and during primary PCI if compared with therapy with heparin and glycoprotein IIb/IIIa inhibitors due to an increase in acute stent thrombosis. Other modalities of infusion have been shown to improve the antithrombotic properties of bivalirudin, maintaining its safety profile. In this article, we discuss on the most recent studies on this drug in the catheterization laboratory during acute myocardial infarction.
Keywords: STEMI, primary PCI, bivalirudin, prolonged infusion, glycoprotein IIb/IIIa inhibitors, thrombin, heparin, acute stent thrombosis, coronary atherosclerotic plaque, clopidogrel
Current Vascular Pharmacology
Title:In the Bivalirudin Era, Are We Still Looking for a Potent Antiplatelet Agent?
Volume: 10 Issue: 4
Author(s): Bernardo Cortese, Antonino Pitì, Adnan Kastrati and Dirk Sibbing
Affiliation:
Keywords: STEMI, primary PCI, bivalirudin, prolonged infusion, glycoprotein IIb/IIIa inhibitors, thrombin, heparin, acute stent thrombosis, coronary atherosclerotic plaque, clopidogrel
Abstract: Thrombin a key modulator of the complex process involved in coronary obstruction during acute ST-segment elevation myocardial is infarction. A correct and complete thrombin inhibition has to be achieved early in this setting and is complementary with fast and potent antiplatelet treatment. Bivalirudin, a direct thrombin inhibitor, has clearly shown to be an effective tool for acute coronary syndromes managed invasively, contemporarily causing fewer hemorragies. However, its efficacy has been questioned, mostly in cases of inadequate platelet inhibition and during primary PCI if compared with therapy with heparin and glycoprotein IIb/IIIa inhibitors due to an increase in acute stent thrombosis. Other modalities of infusion have been shown to improve the antithrombotic properties of bivalirudin, maintaining its safety profile. In this article, we discuss on the most recent studies on this drug in the catheterization laboratory during acute myocardial infarction.
Export Options
About this article
Cite this article as:
Cortese Bernardo, Pitì Antonino, Kastrati Adnan and Sibbing Dirk, In the Bivalirudin Era, Are We Still Looking for a Potent Antiplatelet Agent?, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812700
DOI https://dx.doi.org/10.2174/157016112800812700 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: “Heterocycle and Hydrocarbon Compounds from Natural Sources in Medicinal Chemistry: From Synthesis to Computational Design in Pharmacological Applications” – Part 1)
Current Topics in Medicinal Chemistry An Insight into Molecular Mechanisms and Novel Therapeutic Approaches in Epileptogenesis
CNS & Neurological Disorders - Drug Targets Allograft-Induced Proliferation of Vascular Smooth Muscle Cells: Potential Targets for Treating Transplant Vasculopathy
Current Vascular Pharmacology Microvascular Diseases: Is A New Era Coming?
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Hsp70 in Cancer Growth and Survival
Protein & Peptide Letters Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Current Cardiology Reviews Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine
Current Pharmaceutical Design Resveratrol Improves Cardiovascular Function in DOCA-Salt Hypertensive Rats
Current Pharmaceutical Biotechnology Applications of Nucleic Acid Drugs for Organ Transplantation
Current Topics in Medicinal Chemistry Mechanical Circulatory Support in Children
Current Cardiology Reviews Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Repurposing Metformin for Vascular Disease
Current Medicinal Chemistry Prognostic Value of Leukocytosis in Acute Coronary Syndromes: The Cinderella of the Inflammatory Markers
Current Medicinal Chemistry Mechanisms in the Development of Multiple Sclerosis Lesions: Reconciling Autoimmune and Neurodegenerative Factors
CNS & Neurological Disorders - Drug Targets Nanotechnology and Applied Combustion: Use of Nanostructured Materials for Light-Activated Distributed Ignition of Fuels with Propulsion Applications
Recent Patents on Space Technology Palmitic Acid Grafted Maize Starch (PAgMS) Nanoparticles as Potential Drug Carrier for Irbesarten: In Vitro and In Vivo Evaluation
Current Nanomedicine Exploration of the Two-Way Adjustment Mechanism of <i>Rhei Radix</i> et <i>Rhizoma</i> for Cardiovascular Diseases
Combinatorial Chemistry & High Throughput Screening Proteomics to Unravel Platelet-Related Diseases and Identify Novel Anti-Platelet Drugs
Current Medicinal Chemistry Quantitative Structure-Activity Relationships for Commercially Available Inhibitors of COX-2
Medicinal Chemistry Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
Current Vascular Pharmacology